Chen-Chen Kan

Title: Innovations of Chen-Chen Kan in Protein Engineering

Introduction

Chen-Chen Kan is a notable inventor based in Del Mare, California. He has made significant contributions to the field of protein engineering, particularly in the study of vascular endothelial growth factor receptor-2 (VEGFR2/KDR). With a total of 5 patents, his work has implications for therapeutic advancements in various disease conditions.

Latest Patents

One of Chen-Chen Kan's latest patents involves modifications of the VEGF receptor-2 protein and methods of use. He has determined a 2.4 Å crystal structure of a protein construct containing the catalytic kinase domain of VEGFR2/KDR in an unliganded, phosphorylated state. This innovative protein construct includes a modified catalytic linker and demonstrates comparable in vitro kinase activity to constructs containing the entire KID. The resulting construct not only retains similar in vitro kinase activity to that of the wild-type KID but also allows for complete crystallization of the protein, enabling characterization through X-ray crystallography. The invention further discloses the use of X-ray crystallographic data for the identification and construction of potential therapeutic compounds aimed at treating various disease conditions.

Career Highlights

Chen-Chen Kan is currently employed at Agouron Pharmaceuticals, Inc., where he continues to advance his research in protein engineering. His work is pivotal in understanding the mechanisms of angiogenesis and developing therapeutic strategies.

Collaborations

Some of his notable coworkers include Michael R. Gehring and Camran V. Parast, who contribute to the collaborative efforts in their research endeavors.

Conclusion

Chen-Chen Kan's innovative work in protein engineering, particularly with VEGFR2/KDR, showcases his commitment to advancing therapeutic solutions. His contributions are significant in the ongoing quest to develop effective treatments for various diseases.